drugset / Trial / NCT01435395
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
Phase 1
Completed
12 enrolled
Emory University
Genentech, Inc. · collabMillennium Pharmaceuticals, Inc. · collabSchering-Plough · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center (Emory University), open-label, single arm, phase I study to assess safety and toxicity of bortezomib in combination with bevacizumab and escalating doses of temozolomide for patients with recurrent glioblastoma multiforme. Patients requiring anti-epileptic medications will have to be at least 10 days off EIAEDs. Only non-EIAEDs are accepted.
Timeline
- Start
- 2011-12
- Primary completion
- 2016-04
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
| Subject | Temozolomide | Small molecule | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |